PRC
FPRX

Pearl River Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Pearl River Capital’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-500
Closed -$5K – 938
2018
Q4 		$5K Buy
+500
New +$5.95K 0.02% 728

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pearl River Capital's FPRX Position: Q1 2019 in Review

Pearl River Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2019, closing a stake of 500 shares — an estimated $5K sold.

Pearl River Capital first reported a position in FPRX in Q4 2018 and held it in 1 quarter. The position peaked at $5K in Q4 2018. 113 funds tracked by Wall St. Rank hold FPRX as of Q1 2019.

  • Pearl River Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Pearl River Capital sold 500 Five Prime Therapeutics, Inc. shares in Q1 2019, an estimated $5K.
  • Pearl River Capital first reported a position in Five Prime Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
  • Pearl River Capital's Five Prime Therapeutics, Inc. position peaked at $5K in Q4 2018.
  • 113 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.